Amneal Welcomes Robert Loewenstein, Esq. as General Counsel/Senior Vice President

Amneal Welcomes Robert Loewenstein, Esq. as General Counsel/Senior Vice President


HAUPPAUGE, N.Y.--(BUSINESS WIRE)--Dec 9, 2010 - Amneal Pharmaceuticals, LLC is pleased to announce that Robert Loewenstein, Esq. has joined the company as General Counsel/Senior Vice President.

Mr. Loewenstein was previously a member of the law firm Budd Larner, P.C. in Short Hills, NJ, where he was head of the firm's corporate generic pharmaceuticals practice.

For the past twenty years, Mr. Loewenstein has represented numerous domestic and foreign generic pharmaceutical companies in both U.S. and international transactions. These activities have included the acquisition of a U.K. generic drug manufacturer, the creation of South African joint ventures, the formation of a strategic alliance with an Eastern European generic company for the U.S. market, product collaboration arrangements, product and technology in-licensing and out-licensing agreements and acquisition and dispositions of U.S. product portfolios.

Since the fall of 2005, Mr. Loewenstein has represented Amneal in virtually all of its business activities, including the acquisition of Akyma Pharmaceuticals, KVD Pharmaceuticals and Interpharm, Inc., and has been instrumental in Amneal's growth.

Mr. Loewenstein received his law degree from Brooklyn Law School and an L.L.M. in Taxation from New York University School of Law. He received an undergraduate degree in accounting from the State University of New York at Buffalo, and became a certified public accountant while working for the accounting firm of Deloitte Haskins & Sells. He is admitted to practice law in the state of New Jersey and is a member of the New Jersey Bar Association.

"Over the past several years, I have witnessed the extraordinary growth and development of Amneal as an upcoming leader in the generic drug industry," said Mr. Loewenstein. "I look forward to deepening my relationship with the company in providing my guidance and expertise as their General Counsel."

Amneal Pharmaceuticals LLC, with principal offices in Hauppauge, NY, is a U.S.-based firm that develops, manufactures and distributes generic pharmaceuticals regulated and approved by the U.S. FDA. Known as "Generic's New Generation," the company utilizes its newly expanded R&D and manufacturing capabilities to conceive breakthrough developments with lasting impact for a robust product pipeline. Rapid ANDA approvals and diverse product acquisitions are key to Amneal's aggressive growth strategy, as is the company's strong commitment to deep customer relationships and maximum value creation. Amneal delivers high quality products, superior service levels and dynamic value throughout the pharmaceutical industry. For more information, visit www.amneal.com .

 

 

Contact: Amneal Pharmaceuticals, LLC
Jim Luce
Executive Vice President, Sales & Marketing
Direct: 949-610-8018
Fax: 949-610-8218
E-mail: [email protected]
www.amneal.com

 

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.